When will the EVAPORATE study results be published?
A third study will evaluate the reduction of coronary plaque using Vascepa® (icosapent ethyl). This study, titled EVAPORATE ("Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides [200-499 mg/dL] on Statin Therapy"), will be led by Matthew J. Budoff, M.D., Professor, David Geffen School of Medicine at UCLA and program director of Cardiac CT at Harbor-UCLA Medical Center.
EVAPORATE will be the first study to use MDCT to evaluate the effects of icosapent ethyl on plaque characteristics in patients with persistent high triglyceride (TG) levels. MDCT, multidetector computed tomography, is an advanced technology for diagnostic imaging. The EVAPORATE study will be presented as a poster (abstract #143).
When will the EVAPORATE study results be published?
A third study will evaluate the reduction of coronary plaque using Vascepa® (icosapent ethyl). This study, titled EVAPORATE ("Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides [200-499 mg/dL] on Statin Therapy"), will be led by Matthew J. Budoff, M.D., Professor, David Geffen School of Medicine at UCLA and program director of Cardiac CT at Harbor-UCLA Medical Center.
EVAPORATE will be the first study to use MDCT to evaluate the effects of icosapent ethyl on plaque characteristics in patients with persistent high triglyceride (TG) levels. MDCT, multidetector computed tomography, is an advanced technology for diagnostic imaging. The EVAPORATE study will be presented as a poster (abstract #143).